FATE - Fate Therapeutics Inc Stock Price, Fair Value and News

$3.04-0.15 (-4.70%)

Delayed as of 23 Oct 2024, 03:04 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FATE Price Action

Last 7 days

4.6%

Last 30 days

-17.6%

Last 90 days

-38.4%

Trailing 12 Months

77.2%

FATE RSI Chart

FATE Valuation

Market Cap

363.3M

Price/Earnings (Trailing)

-2.07

Price/Sales (Trailing)

29.49

Price/Free Cashflow

-2.57

FATE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FATE Fundamentals

FATE Revenue

Revenue (TTM)

12.3M

Rev. Growth (Yr)

625.83%

Rev. Growth (Qtr)

251.79%

FATE Earnings

Earnings (TTM)

-175.7M

Earnings Growth (Yr)

27.16%

Earnings Growth (Qtr)

19.95%

FATE Profitability

Return on Equity

-44.26%

Return on Assets

-33.23%

Free Cashflow Yield

-38.94%

FATE Investor Care

Shares Dilution (1Y)

15.54%

Diluted EPS (TTM)

-1.71

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.5M	12.3M	0	0
2023	136.9M	119.3M	106.2M	63.5M
2022	63.1M	68.3M	69.0M	96.3M
2021	40.1M	48.0M	54.7M	55.8M
2020	10.6M	13.2M	18.3M	31.4M
2019	6.3M	8.1M	9.5M	10.7M
2018	4.1M	4.1M	4.1M	4.7M
2017	4.1M	4.1M	4.1M	4.1M
2016	3.8M	4.5M	4.5M	4.4M
2015	0	828.0K	1.6M	2.4M
2013	2.7M	1.9M	1.6M	971.0K
2012	1.5M	1.9M	2.3M	2.7M
2011	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

CEO	Mr. J. Scott Wolchko
WEBSITE	fatetherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	551

Fate Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Fate Therapeutics Inc? What does FATE stand for in stocks?

FATE is the stock ticker symbol of Fate Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Fate Therapeutics Inc (FATE)?

As of Tue Oct 22 2024, market cap of Fate Therapeutics Inc is 363.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FATE stock?

You can check FATE's fair value in chart for subscribers.

Is Fate Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether FATE is over valued or under valued. Whether Fate Therapeutics Inc is cheap or expensive depends on the assumptions which impact Fate Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FATE.

What is Fate Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 22 2024, FATE's PE ratio (Price to Earnings) is -2.07 and Price to Sales (PS) ratio is 29.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FATE PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Fate Therapeutics Inc's stock?

In the past 10 years, Fate Therapeutics Inc has provided -0.036 (multiply by 100 for percentage) rate of return.